DepoMed
Recent developments from DepoMed summarized
Published in Aging and Elder Health Week, August 19th, 2007
This trend article is an immediate alert from NewsRx to identify the most recent news developments at DepoMed.
Report 1: Depomed, Inc. (NASDAQ:DEPO) announced today that it has begun dosing patients in the phase 2 trial for Gabapentin GR(TM) for the treatment of menopausal hot flashes.
"We are very excited to have dosed the first patient. Following up on the clinical trial kick-off meeting we held in April, we screened approximately 40 patients last week and dosed four patients yesterday," said Carl Pelzel, executive vice president and chief operating officer of Depomed. "Even though...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Aging and Elder Health Week
More Articles from Aging and Elder Health Week
- Allscripts
Iowa's Largest Health System Selects Emergency Department Information System from Allscripts - Alzheimer Disease
New Alzheimer disease study findings recently were reported by researchers at New York University - Alzheimer Disease
Studies from Ludwig-Maximilians University reveal new findings on Alzheimer disease - Angiotensins
Researchers from Harvard University describe findings in angiotensins - Arthritis
Hip and knee replacements rarely performed in patients over 100 - Asthma
New findings reported from West Virginia University describe advances in asthma in children - More from this issue of Aging and Elder Health Week
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
